Primary Cutaneous CD4+ Small/Medium-Sized T-Cell Lymphoma With Spontaneous Regression After Biopsy

Primary cutaneous CD4+ small‐/medium‐sized T‐cell lymphoproliferative disorder: A case report

“…The lesion size in case described herein was larger than other reported cases (1‐2.5 cm), it might be one of the possible reason why the first‐line therapy failed …”

“…Primary cutaneous CD4+ small‐/medium‐sized T‐cell lymphoproliferative disorder (PCSM‐TCLPD) is a rare and heterogeneous entity, with suggested derivation from follicular T‐helper lymphocytes. Most of the cases present as a solitary lesion in the upper part of the body and good response to surgical excision or local radiotherapy . The report describes a case of this rare disease with some peculiarities compared the typical described forms.…”

Primary cutaneous CD4+ small/medium pleomorphic T‐cell lymphoproliferative disorder: Where do we stand? A systematic review

“…The clinical course of PCSMP‐TLPD is variable. Lesions may wax and wane over a course of weeks to years, or simply resolve spontaneously after a skin biopsy . PCSMP‐TLPD generally has a favorable prognosis and indolent behavior, with 5‐year survival rates of 98.4 % among reported cases, especially with solitary lesions as shown in Table and Figure .…”

“…The optimal treatment for PCSMP‐TLPD has not yet been defined. However, various therapeutic options have been used for solitary lesions, including surgical excision, radiotherapy or a combination of both , as well as topical, intralesional or oral steroids , doxycycline monohydrate , amoxicillin , cryocautery and bexarotene . Systemic chemotherapy (including cyclophosphamide either as monotherapy or in association with prednisolone) , multi‐agent chemotherapy (as cyclophosphamide, hydroxydaunomycin, oncovin and prednisone (CHOP) therapy) and systemic interferon‐alfa have been used for patients with multiple aggressive lesions, which are now considered mostly as true lymphomas rather than cases of PCSMP‐TLPD.…”

Primär kutane CD4+ klein‐ bis mittelgroßzellige pleomorphe T‐Zell‐Lymphoproliferation: Wo stehen wir? Eine systematische Übersicht

“…Der klinische Verlauf der PCSMP‐TLPD variiert. Die Läsionen können im Verlauf von Wochen bis Jahren wachsen und sich verkleinern oder nach einer Hautbiopsie spontan abklingen . Die PCSMP‐TLPD weist generell eine günstige Prognose und ein indolentes Verhalten auf.…”